SAGE-217, a novel GABAA receptor positive allosteric modulator: clinical pharmacology and tolerability in randomized phase i dose-finding studies.
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
SAGE-217, a novel γ-aminobutyric acid A (GABA A ) receptor positive allosteric modulator, was evaluated in phase I, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) studies to assess the safety and pharmacokinetics (PK) of SAGE-217 following administration as an oral solution. In the SAD study, subjects were randomized 6:2 to a single dose of SAGE-217 or placebo. Doses ranged from 0.25 to 66 mg across nine cohorts. In the MAD study, subjects were randomized 9:3 and received SAGE-217 (15, 30, or 35 mg) or placebo once daily for 7 days. In both studies, PK, maximum tolerated dose (MTD; against predetermined criteria), safety, and tolerability were assessed. A total of 108 healthy volunteers enrolled in the studies—72 subjects in the SAD study and 36 subjects in the MAD study. SAGE-217 was orally bioavailable, with a terminal-phase half-life of 16–23 h and a t max of approximately 1 h. The MTDs for the oral solution of SAGE-217 in the SAD and MAD studies were determined to be 55 and 30 mg daily, respectively. In both studies, SAGE-217 was generally well tolerated, and no serious adverse events (SAEs) were reported. Most AEs were mild, dose-dependent, transient, occurred around the t max , and related to drug pharmacology. SAGE-217 was generally well tolerated, and its PK profile was well characterized. Based on this profile, SAGE-217 has been advanced into multiple phase II clinical programs and pivotal studies of major depressive disorder and postpartum depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Zuranolone (SAGE-217; Sage Therapeutics, Inc) is an investigational NAS GABAAR PAM with a similar mechanism of action and a pharmacokinetic profile suitable for once-daily oral dosing.39”
From Effect of Zuranolone vs Placebo in Postpartum Depression (2021) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“NAS GABAAR PAMs have pharmacological profiles and binding sites distinct from benzodiazepines,40,41 with the ability to modulate the activity of both synaptic and extrasynaptic GABAARs.39,42”
From Effect of Zuranolone vs Placebo in Postpartum Depression (2021) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
Quantification of Sleepiness: A New Approach
Hoddes, E., Zarcone, V., Smythe, H., Phillips, R., & Dement, W. C. (1973) · Psychophysiology · doi:10.1111/j.1469-8986.1973.tb00801.x · Cited by 2,538
Validity and Reliability of the Observer??s: Assessment of Alertness/Sedation Scale
CHERNIK, D. A., GILLINGS, D., LAINE, H., HENDLER, J., SILVER, J. M., DAVIDSON, A. B., SCHWAM, E. M., & SIEGEL, J. L. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199008000-00003 · Cited by 1,246
The GABAergic deficit hypothesis of major depressive disorder
Luscher, B., Shen, Q., & Sahir, N. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.120 · Cited by 934
GABAergic Mechanisms in Epilepsy
Treiman, D. M. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.042suppl.3008.x · Cited by 836
Meltzer-Brody, S., Colquhoun, H., Riesenberg, R., Epperson, C. N., Deligiannidis, K. M., Rubinow, D. R., Li, H., Sankoh, A. J., Clemson, C., Schacterle, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31551-4 · Cited by 795
Self-citationBrexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.
Kanes, S., Colquhoun, H., Gunduz-Bruce, H., Raines, S., Arnold, R., Schacterle, A., Doherty, J., Epperson, C. N., Deligiannidis, K. M., Riesenberg, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31264-3 · Cited by 479
Self-citationLener, M. S., Niciu, M. J., Ballard, E. D., Park, M., Park, L. T., Nugent, A. C., & Zarate, C. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.005 · Cited by 468
Extrasynaptic GABA A Receptors: Form, Pharmacology, and Function
Belelli, D., Harrison, N. L., Maguire, J., Macdonald, R. L., Walker, M. C., & Cope, D. W. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3340-09.2009 · Cited by 464
The role of reproductive hormones in postpartum depression
Schiller, C. E., Meltzer-Brody, S., & Rubinow, D. R. (2015) · CNS Spectrums · doi:10.1017/s1092852914000480 · Cited by 451
Cited by
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Effect of Zuranolone vs Placebo in Postpartum Depression
Deligiannidis, K. M., Meltzer-Brody, S., Gunduz-Bruce, H., Doherty, J., Jonas, J., Li, S., Sankoh, A. J., Silber, C., Campbell, A. D., Werneburg, B., et al. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.1559 · Cited by 277
Self-citationCutler, A. J., Mattingly, G. W., & Maletic, V. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02514-2 · Cited by 192
Althaus, A. L., Ackley, M. A., Belfort, G. M., Gee, S. M., Dai, J., Nguyen, D. P., Kazdoba, T. M., Modgil, A., Davies, P. A., Moss, S. J., et al. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108333 · Cited by 135
“Phase 1 studies in healthy volunteers have demonstrated that zuranolone was generally well tolerated and exhibited predictable pharmacokinetics following oral administration (Hoffmann et al., 2019).”
BackgroundSelf-citationAllopregnanolone-based treatments for postpartum depression: Why/how do they work?
Walton, N., & Maguire, J. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100198 · Cited by 103
Metadata
- Authors
- Hoffmann, E., Nomikos, G. G., Kaul, I., Raines, S., Wald, J., Bullock, A., Sankoh, A. J., Doherty, J., Kanes, S. J., & Colquhoun, H.
- Affiliations
- Sage Therapeutics (United States) (US)
- Biogen (United States) (US)
- Corresponding author
- Hoffmann, Ethan
- Venue
- Clinical Pharmacokinetics
- Published
- 2019-07-24
- Volume
- 59
- Issue
- 1
- Pages
- 111-120
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- PMC
- PMC6994455
- OpenAlex
- W2963972855
- Cited by
- 59
- References
- 30
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 18 · 2023: 14 · 2022: 5 · 2021: 7 · 2020: 7 · 2019: 3
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Sage Therapeutics, Inc.
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- GABAA receptor, positive allosteric modulators, pharmacokinetics, tolerability, maximum tolerated dose, dose-finding, healthy volunteers, major depressive disorder, postpartum depression, oral bioavailability
- MeSH terms
- Administration, Oral, Adult, Allosteric Regulation, Major Depressive Disorder, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Pharmacology, Clinical, Placebos, Pregnanes, Pregnanolone, Pyrazoles, Safety, Depression, Postpartum, GABA-A Receptor Agonists, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SAGE-217, a novel GABAA receptor positive allosteric modulator: clinical pharmacology and tolerability in randomized phase i dose-finding studies. https://app.cochat.ai/papers/10.1007/s40262-019-00801-0
- The paper
- Hoffmann, E., Nomikos, G. G., Kaul, I., Raines, S., Wald, J., Bullock, A., Sankoh, A. J., Doherty, J., Kanes, S. J., & Colquhoun, H. (2020). SAGE-217, a novel GABAA receptor positive allosteric modulator: clinical pharmacology and tolerability in randomized phase i dose-finding studies. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-019-00801-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.